Advanced search
Publication Cover
Clinical, Cosmetic and Investigational Dermatology Volume 16, 2023 - Issue
Submit an article Journal homepage
617
Views
3
CrossRef citations to date
0
Altmetric
CLINICAL TRIAL REPORT

A Randomized, Controlled Clinical Trial of a Dermocosmetic Containing Vichy Volcanic Mineralizing Water and Probiotic Fractions in Subjects with Rosacea Associated with Erythema and Sensitive Skin and Wearing Protective Masks

Enzo Berardesca1 Phillip Frost Department of Dermatology, University of Miami, Miami, FL, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-3423-5038View further author information
ORCID Icon,
Adriana Bonfigli2 Clinical Evaluations, ISPE, Milano, ItalyORCID Iconhttps://orcid.org/0000-0002-1773-2019View further author information
ORCID Icon,
Claudia Cartigliani2 Clinical Evaluations, ISPE, Milano, ItalyView further author information
,
Delphine Kerob3 International Scientific Affairs, Cosmetic Active International, Levallois-Perret, FranceView further author information
&
Jerry Tan4 Department of Medicine and Windsor Clinical Research Inc Western University, Windsor, ON, CanadaORCID Iconhttps://orcid.org/0000-0002-9624-4530View further author information
ORCID Icon
Pages 71-77 | Received 30 Sep 2022, Accepted 05 Jan 2023, Published online: 11 Jan 2023

Figures & data

Figure 1 Skin sensitivity at baseline, Day 15 and Day 30. M89PF significantly (p<0.0001) reduced skin sensitivity as early as Day 15.

Figure 1 Skin sensitivity at baseline, Day 15 and Day 30. M89PF significantly (p<0.0001) reduced skin sensitivity as early as Day 15.

Figure 2 Instrumental assessments at baseline, Day 15 and Day 30. M89PF significantly (p<0.0001) improved erythema, skin hydration and transepidermal water loss as early as Day 15 compared to the standard skin care. (A) Erythema. (B) Skin hydration. (C) Transepidermal water loss.

Figure 2 Instrumental assessments at baseline, Day 15 and Day 30. M89PF significantly (p<0.0001) improved erythema, skin hydration and transepidermal water loss as early as Day 15 compared to the standard skin care. (A) Erythema. (B) Skin hydration. (C) Transepidermal water loss.

Figure 3 Clinical signs and symptom scores at baseline, Day 15 and Day 30. M89Pf significantly (p<0.0001) reduced clinical signs and symptoms as early as Day 15.

Figure 3 Clinical signs and symptom scores at baseline, Day 15 and Day 30. M89Pf significantly (p<0.0001) reduced clinical signs and symptoms as early as Day 15.

Figure 4 Subject satisfaction after 15 and 30 days of use of M89PF.

Figure 4 Subject satisfaction after 15 and 30 days of use of M89PF.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.